Search Results
Eunice Wang, MD, on incorporating Vyxeos (liposomal daunorubicin and cytarabine) in AML treatment
Eunice Wang, MD, on the importance of drug potency in the treatment of FLT3-ITD positive AML
Eunice Wang, MD, considers approaches for clinicians when managing frail AML patients
Eunice S. Wang, MD, discusses the toxicity of the CPX-351 (Vyxeos) in a phase III study
Eunice S. Wang, MD, on Abstract 7008 & Crenolanib potential activity in relapsed FLT3 positive AML
Keith Pratz, MD, explains how he is incorporating Vyxeos into his treatment of AML patients
Liposomal daunorubicin and cytarabine in R/R ALL
CPX-351: liposomal daunorubicin/cytarabine for AML
CPX-351: liposomal daunorubicin and cytarabine for treating high-risk AML
CPX-351 liposome injection vs standard cytarabine and daunorubicin for older high-risk AML patients
Considerations for CPX-351 in Acute Myeloid Leukemia
Lifting limits: liposomal delivery of chemotherapy for secondary AML with CPX-351
